All News
ACR24: Rheumatology Roundup
Join Drs. Jack Cush and Artie Kavanaugh as they review 15+ presentations and abstracts from the 2024 ACR Convergence meeting in Washington, DC.
Read Article
Novel TYK2 inhibitor Zasocitinib
Interest in tyrosine kinase 2 (TYK2), a member of the JAK family, is growing following the success of JAK inhibitors in treating rheumatic diseases. TYK2 is crucial for immune activation but has minimal involvement in metabolic and hematopoietic… https://t.co/eDcx4AAnAs https://t.co/Y8Rso7h5t2
Dr. John Cush RheumNow ( View Tweet)
Autoantibodies, found in over half of adult and paediatric patients with idiopathic inflammatory myopathies (IIMs), these correlate with clinical phenotypes, aiding in classification and prognosis. https://t.co/ZRXqtEec6s https://t.co/jkUe9bRlmU
Dr. John Cush RheumNow ( View Tweet)
ANA+ and no Autoimmune Disease? Check the liver
Dr. Janet Pope discusses abstract 0627, presented at #ACR24.
https://t.co/4HV2kqjibL https://t.co/kmVcvUZtRQ
Dr. John Cush RheumNow ( View Tweet)
💊Litifilimab- another new molecule for SLE
Anti BDCA2 🎯
In cutaneous lupus👉
👉Decrease CLASI score
👉Decrease IFN induced MxA expression
#ACR2024 #ACRAmbassador https://t.co/AeJOGhVXIR
Ritasman Baisya RitasmanB ( View Tweet)
#ACR24: What Exactly do JAKs and TYKs Do?
Let me start by confessing something embarrassing: the immune system is just too complex for me to understand. I suspect the onslaught of new drugs with new mechanisms at ACR 2024 may have left many of you feeling similarly.… https://t.co/HkhZJBxDdO https://t.co/xYeSpHS2dD
Dr. John Cush RheumNow ( View Tweet)
COVID Associated Immune Disease
Dr. Len Calabrese reports on a session he participated in discussing if Covid-19 is associated or causal for autoimmune disease. Reporting from #ACR24
https://t.co/vFdlf9XVzf https://t.co/JhpglNVIt7
Links:
Dr. John Cush RheumNow ( View Tweet)
Hypoxia seems to exacerbate neutrophil activation by ANCA
- enhanced F-Actin polymerization
- enhanced NET formation
Could hypoxia predilection in certain tissues (kidney, lung) lead to the AAV phenotypic disease patterns?
@RheumNow #ACR24 https://t.co/KxaeMvkd2t
Links:
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Prior studies have shown that IFN is increased in non-lesional skin of SLE pts.
In this study, they found a ⬆️ expression of IFN stimulated genes (ISGs) in pts w/ a history of CLE.
No correlation w/ CLASI act & IFN scores but only few pts.
@RheumNow #ACR24 abs2678 https://t.co/cPT6yPkoCb
Links:
sheila RHEUMarampa ( View Tweet)
Late breaking abstract L17
CAR-NK Therapy for Refractory SLE.
In a trial of 20 severe SLE patients:
- 75% achieved LLDAS, 50% achieved DORIS remission at 6 months
- B cell reconstitution: 2–3 months post-treatment
- Safety: 2 mild cytokine release syndrome with fever; no severe… https://t.co/MS8cutm48o
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Mitochondria: the powerhouse of the cell—but the fuel behind gout flares?
#ACR24 @RheumNow https://t.co/lV4dovLV18
Akhil Sood MD AkhilSoodMD ( View Tweet)
In prelim analysis of this controlled clinical trial, SLE pts w/ active dse who weres given addtl NAC for 3 mos had significantly reduced dse activity.
Mechanism? NAC reduces rapamycin (mTOR) activation.
Common AEs: nausea, vomiting
@RheumNow #ACR24 abs2677 https://t.co/E4w2Qd7RwP
Links:
sheila RHEUMarampa ( View Tweet)
#Positive #RCT of #Nipocalimab a FcRn receptor inhibitor in #Sjogrens #Disease
👏Phase 2 +RCT
ESSSDAI and ESPRI both improved
🤷♀️what it means to lower #antibodoes #Ro #La
Excited for Phase 3 results
#ACRBest #ACR24 @RheumNow @ACRheum abst#2527 https://t.co/NeeYT7VR16
Links:
Janet Pope Janetbirdope ( View Tweet)
Autoantibody tests are everywhere, but how do we make sense of them? With the proper algorithms, can we go beyond interpretation to predicting autoimmunity before it develops?
Check out my article: Taking the AI out of AutoImmunity
https://t.co/d3ZNYWQaaQ
@RheumNow #ACR24
Akhil Sood MD AkhilSoodMD ( View Tweet)
Paraoxonase-1: Possible Biomarker for Progression to RA
Dr. Jonathan Kay discusses abstract 0464, Increases in Paraoxonase-1 Activity over Time Associates with Reduced Risk of Incident Inflammatory Arthritis in an Anti-Citrullinated Protein Antibody-Positive Population,… https://t.co/yhcCrrvjxH https://t.co/caf5dUvrOQ
Dr. John Cush RheumNow ( View Tweet)
Pathophysiological pathways in neuropsychiatric SLE. 2 components:
-Ischaemic
-Inflammatory
Zahi Touma @RheumNow #ACR24 https://t.co/wwlSSSpOIU
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Sullivan et al. Vasculitis in VEXAS. 81 patients. 27% vasculitis. Cutaneous SVV 20%, AAV 2.5%, cutaneous MVV 2.5%, LVV 2.5%. @RheumNow #ACR24 Abstr#2651 https://t.co/AV3RcuSKpV https://t.co/xrax025TzP
Links:
Richard Conway RichardPAConway ( View Tweet)
Neuropsychiatric manifestations in SLE.
Susanne Benseler MD @RheumNow #ACR24 https://t.co/subiykC5Q4
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Diagnostic work up for neuropsychiatric SLE. Zahi Touma MD @RheumNow #ACR24 https://t.co/zLX1QHCaSu
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Very informative slide describing the 2 NPSLE pathogenetic pathways & their differences in mediators, mechanisms and NP events.
@RheumNow #ACR24
@rheumarhyme @theactiverheum https://t.co/D3XFDqxMBq
sheila RHEUMarampa ( View Tweet)
